{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:11:53Z","timestamp":1778785913720,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> CD40 and CD40L have been reported as associated with aortic dissection (AD) and aortic aneurysm (AA), but the causality of the associations has not been established yet.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We conducted a two-sample Mendelian randomization (MR) study to assess the causal inference between CD40\/CD40L and aortic diseases including AD and AA. The instrumental variables (IVs) for CD40 and CD40L were selected from a high-quality protein quantitative trait loci dataset released by a genomic study involving 30,931 individuals of European ancestry. The genome-wide association studies summary statistics for AD and AA were from the FinnGen Release 7, with 288638 controls for all outcomes of interests, 680 cases for AD and 6,092 cases for AA, also from European ancestry. For AA subtypes, there were 5,881 cases of thoracic AA (TAA) and 2,434 cases of abdominal AA (AAA) respectively. Inverse-variance weighted and Wald ratio were applied for calculating causal estimates. Horizontal pleiotropy and heterogeneity were assessed using MR-Egger regression analysis and Cochran Q test, respectively. Leave-one-out analyses were further performed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Three single-nucleotide polymorphisms (SNPs) for CD40 and one SNP for CD40L were selected as IVs. We found genetic proxied CD40 levels inversely associated with the risk of AD (odds ratio [OR]: 0.777, 95% confidence interval [CI]: 0.618\u20130.978, <jats:italic>p<\/jats:italic> = 0.031) and AA (OR: 0.905, 95% CI: 0.837\u20130.978, <jats:italic>p<\/jats:italic> = 0.012), consistent across TAA (both <jats:italic>p<\/jats:italic> &amp;lt; 0.050). There were trends of increased risks of AD and AA in the presence of CD40L while not reaching statistical significance. No significant horizontal pleiotropy or heterogeneity was observed.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our MR study provides evidence supporting the causal association between CD40 and the reduced risks of both AD and AA.<\/jats:p>","DOI":"10.3389\/fgene.2022.998525","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T04:56:00Z","timestamp":1667969760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Causal associations between CD40\/CD40L and aortic diseases: A mendelian randomization study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianming","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaogang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a beta3 integrin\u2014Dependent mechanism","volume":"8","author":"Andr\u00e9","year":"2002","journal-title":"Nat. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacc.2009.03.076","article-title":"The CD40\/CD40 ligand system: Linking inflammation with atherothrombosis","volume":"54","author":"Antoniades","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41569-020-00472-6","article-title":"Epidemiology and management of aortic disease: Aortic aneurysms and acute aortic syndromes","volume":"18","author":"Bossone","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/ije\/dyw220","article-title":"Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-egger regression: The role of the I2 statistic","volume":"45","author":"Bowden","year":"2016","journal-title":"Int. J. Epidemiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","article-title":"CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies","volume":"19","author":"Bullock","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1177\/0962280215597579","article-title":"A review of instrumental variable estimators for Mendelian randomization","volume":"26","author":"Burgess","year":"2017","journal-title":"Stat. Methods Med. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"E8533","DOI":"10.3390\/ijms21228533","article-title":"CD40\/CD40L and related signaling pathways in cardiovascular health and disease-the pros and cons for cardioprotection","volume":"21","author":"Daub","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","article-title":"Mendelian randomization","volume":"318","author":"Emdin","year":"2017","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1093\/eurheartj\/ehu281","article-title":"2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC)","volume":"35","author":"Erbel","year":"2014","journal-title":"Eur. Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"Am. J. Transpl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1096","DOI":"10.1212\/NXI.0000000000001096","article-title":"Safety and immune effects of blocking CD40 ligand in multiple sclerosis","volume":"8","author":"Fadul","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s42255-020-00287-2","article-title":"Genomic and drug target evaluation of 90 cardiovascular proteins in 30, 931 individuals","volume":"2","author":"Folkersen","year":"2020","journal-title":"Nat. Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.18632\/aging.101651","article-title":"Correction: CD40L promotes development of acute aortic dissection via induction of inflammation and impairment of endothelial cell function","volume":"10","author":"Han","year":"2018","journal-title":"Aging"},{"key":"B15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00395-013-0386-5","article-title":"CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction","volume":"108","author":"Hausding","year":"2013","journal-title":"Basic Res. Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa022600","article-title":"Soluble CD40 ligand in acute coronary syndromes","volume":"348","author":"Heeschen","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nature21683","article-title":"KRAB zinc-finger proteins contribute to the evolution of gene regulatory networks","volume":"543","author":"Imbeault","year":"2017","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"dgz013","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-A proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-cd154: A randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/ATVBAHA.117.310640","article-title":"CD40L deficiency protects against aneurysm formation","volume":"38","author":"Kusters","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","article-title":"LDlink: A web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants","volume":"31","author":"Machiela","year":"2015","journal-title":"Bioinforma. Oxf. Engl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fcvm.2017.00040","article-title":"CD40L and its receptors in atherothrombosis-an update","volume":"4","author":"Michel","year":"2017","journal-title":"Front. Cardiovasc. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41586-020-2493-4","article-title":"Expanded encyclopaedias of DNA elements in the human and mouse genomes","volume":"583","author":"Moore","year":"2020","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1161\/ATVBAHA.120.313991","article-title":"Aortic aneurysms and dissections series","volume":"40","author":"Shen","year":"","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1161\/ATVBAHA.120.313804","article-title":"Aortic aneurysms and dissections series: Part II: Dynamic signaling responses in aortic aneurysms and dissections","volume":"40","author":"Shen","year":"","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/cvr\/cvz206","article-title":"Functional association of a CD40 gene single-nucleotide polymorphism with the pathogenesis of coronary heart disease","volume":"116","author":"Sultan","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.2353\/ajpath.2006.050868","article-title":"Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution","volume":"168","author":"Touat","year":"2006","journal-title":"Am. J. Pathol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/eurheartj\/ehi132","article-title":"Soluble CD40 ligand in acute and chronic heart failure","volume":"26","author":"Ueland","year":"2005","journal-title":"Eur. Heart J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12979-016-0063-2","article-title":"Acute phase of aortic dissection: A pilot study on CD40L, MPO, and MMP-1, -2, 9 and TIMP-1 circulating levels in elderly patients","volume":"13","author":"Vianello","year":"2016","journal-title":"Immun. Ageing"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.998525\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T04:56:01Z","timestamp":1667969761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.998525\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":32,"alternative-id":["10.3389\/fgene.2022.998525"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.998525","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"998525"}}